Samsung and Bioepis launch third Humira biosimilar in Europe
October 17, 2018Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …
Roche signs $1 billion deal with cell therapy firm SQZ biotech
October 17, 2018Research and Development Roche, SQZ, collaboration, deal, oncology
The Massachusetts-based cell therapy company SQZ Biotech, has announced the expansion of its collaboration with Swiss pharma giant Roche, in …
Fewer patents being filed for novel infectious diseases and AMR diagnostic technologies; US leads, UK follows
October 17, 2018Research and Development AMR, IP, intellectual property, patents
Fewer patents are being filed for point-of-care diagnostic technologies aimed at tackling infectious diseases and antimicrobial resistance (AMR), according to …
FDA approves Pfizer’s Talzenna for breast cancer alongside tool to identify eligible patients
October 17, 2018Research and Development, Sales and Marketing Cancer, FDA, Pfizer, Talzenna, breast cancer, pharma
Pfizer’s Talzenna (talazoparib) has secured FDA approval, it has emerged. The poly (ADP-ribose) polymerase (PARP) inhibitor is now set to …
Prescription painkillers reclassified amid addiction concerns
October 17, 2018Research and Development UK, addiction, classification, painkillers, policy
Two commonly prescribed painkillers are set to be put under tighter controls in the United Kingdom after a number of …
Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk
October 16, 2018Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma
Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …
Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug
October 16, 2018Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD
Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning …
Trump administration propose ruling requiring price transparency on TV ads
October 16, 2018Manufacturing and Production Alex Azar, Drug pricing, Trump, access, adverts
US Health and Human Services Secretary Alex Azar, has announced a proposal which would require pharma firms to include the …
Amgen launches first biosimilar of best-selling Humira in Europe
October 16, 2018Manufacturing and Production, Sales and Marketing Amgen, Amgevita, Humira, biosimilar, pharma
Amgen has announced the launch of a proprietary biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) across all European markets, …
AstraZeneca halting UK investment due to Brexit uncertainty
October 15, 2018Manufacturing and Production AstraZeneca, Le Monde, UK, brexit, no-deal
The Anglo-Swedish pharma firm AstraZeneca has suspended investment into the United Kingdom, due to the uncertainty surrounding Brexit. The firm’s …
MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes
October 15, 2018Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma
MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …
AI, big data: Making a case for faster drug discovery
October 15, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Big Data, feature, healthcare, research
They’re two of the biggest buzzwords getting professionals excited across pharma – Anjali Shukla explores the ways in which AI …
FDA advisory panel approves AcelRx’s opioid pain drug Dsuvia
October 15, 2018Sales and Marketing FDA, approval, comittee, opioids
An FDA advisory panel voted 10 to 3 to recommend the approval of AcelRx Pharmaceuticals’ opioid pain drug Dsuvia (sufentanil) …
Digital system may prevent £300m prescription fraud losses for NHS by 2020
October 15, 2018Sales and Marketing NHS, fraud, government, prescription fraud, uk politics
The British government are launching a new digitised system aimed at cracking down on prescription fraud in the NHS. However …
BMS’ Opdivo fails to improve overall survival in small-cell lung cancer
October 15, 2018Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma
Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …
Health innovation system is broken and failing patients, new report argues
October 15, 2018Sales and Marketing IP, industry, intellectual property, priofit, research
The pharmaceutical industry is incentivised to set high prices and deliver short-term returns to shareholders, rather than focusing on riskier, …
Novo Nordisk’s Fiasp shows strong blood sugar control in under-18 type 1 diabetes patients
October 12, 2018Medical Communications, Research and Development Fiasp, Novo Nordisk, Type 1 diabetes, diabetes, pharma
New data unveiled by Novo Nordisk has shown that its insulin injection Fiasp (fast-acting insulin aspart) could provide a better …
Top Ten most popular articles on Pharmafile.com this week
October 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing WHO, biosimilars. GSK, manufacturing, pharma, top 10
Politics played a big role in pharma this week after Trump introduced legislation aimed at reducing the price of drugs. …
Trevena’s opioid injection fails to win over FDA committee
October 12, 2018Medical Communications, Sales and Marketing FDA, Trevena, US, oliceridine, opioid, opioid crisis, pharma
Trevena has seen its opioid injection oliceridine fail to win over an FDA advisory panel in the management of acute …
Chanelle Pharma announces €86m investment over next five years
October 12, 2018Medical Communications Ireland, chanelle, generics, investment, research
Chanelle Pharmaceuticals, one of the largest Irish-owned pharmaceutical companies in Ireland, have announced an €86 million investment programme over the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
